See the DrugPatentWatch profile for protopic
FDA Approval for Children
Protopic (tacrolimus ointment) is FDA-approved for children aged 2 years and older with moderate to severe atopic dermatitis when other treatments fail. It's available in 0.03% strength specifically for this group, with 0.1% for adults and older kids.[1][2]
Safety Data from Clinical Trials
Trials showed Protopic clears or nearly clears eczema in about 30-50% of children after 3 months, with similar safety to adults. Common side effects include burning or stinging at the application site (up to 50% initially, fading over time), flu-like symptoms, and headache. Serious infections occurred in 0.9% of pediatric patients vs. 0.5% in adults.[1][3]
Key Safety Concerns and Black Box Warning
Protopic carries a black box warning for rare cancer risk (skin cancer, lymphoma), based on animal studies and case reports. Long-term studies up to 4 years in children found no increased cancer rate, but the FDA advises using the lowest effective dose for shortest duration. Avoid on infected skin or with occlusive dressings.[1][2][4]
Guidelines for Use in Kids
Apply thinly twice daily to affected areas only. Limit to 10% of body surface. Don't use under 2 years without doctor advice. Wash hands after, and monitor for infections or excessive warmth/redness. Safe in pregnancy category C, but data is limited.[1][5]
Long-Term Risks and Monitoring
No evidence of growth suppression or immune weakening in studies up to 4 years. Yearly skin exams recommended for long-term users. Discontinue if lymph nodes swell persistently.[3][4]
Alternatives if Safety Worries You
Topical steroids (e.g., hydrocortisone) are first-line but risk skin thinning. Newer options like Dupixent (dupilumab) injections for severe cases in kids 6 months+, with fewer local reactions but higher cost.[2][5]
[1]: FDA Label for Protopic
[2]: American Academy of Dermatology Guidelines
[3]: Pediatric Trial Data (NEJM 2001)
[4]: Post-Marketing Safety Review (FDA 2005)
[5]: UpToDate: Atopic Dermatitis in Children